FDA gives AstraZeneca's ENHERTU a bigger lane

Another green light for ENHERTU

The FDA has approved AstraZeneca and Daiichi Sankyo’s ENHERTU for patients with HER2-positive early breast cancer, and this one covers both neoadjuvant and adjuvant treatment. In plain English: doctors can use it before surgery and after surgery, which means the drug just picked up a bigger slice of the treatment journey.

Why investors should care

This is the kind of label expansion pharma loves because it turns a promising drug into a more useful one. More eligible patients usually means more revenue runway, and ENHERTU has already been one of the big engines in AstraZeneca’s oncology story. If the drug keeps stacking approvals, it starts looking less like a one-hit wonder and more like a franchise.

The fine print

• The approval is based on results from DESTINY-Breast11.
• The target population is HER2-positive early breast cancer.
• The new label covers both neoadjuvant and adjuvant settings, so the treatment can be used around surgery, not just in one narrow window.

Big picture

AstraZeneca keeps doing what big pharma dreams about: taking one successful asset and squeezing every last ounce of commercial juice out of it. For shareholders, that’s usually the difference between a good oncology drug and a great one.